2022 Northwest Pharmacy Network (NPN) Annual Virtual Meeting
Participants will hear from three subject matter experts on a wide variety of topics. They will have a chance to raise questions and/or provide comments based on their own experiences and gain knowledge from each other during the presentations.
340B Drug Discount Program Updates:
340B Drug Pricing Program covered entities must ensure program integrity and maintain accurate records documenting compliance with all 340B Program requirements.
HRSA has the authority to audit covered entities for compliance with 340B Drug Pricing Program (340B Program) requirements (42 USC 256b(a)(5)(C)):
Covered entities are subject to audit by the manufacturer or the federal government. Failure to comply may make the 340B covered entity liable to manufacturers for refunds of discounts or cause the covered entity to be removed from the 340B Program.
HRSA's Program Integrity guiding principles are to maximize oversight reach and manage compliance risks. Efforts to follow these principles include audits of covered entities and manufacturers to enforce requirements for these stakeholders.
Biomarker Utilization in the Evaluation of Infection:
There be a thorough review of the biomarkers IL-6, CRP, and Procalcitonin. Literature will be evaluated for utilization of these biomarkers in diagnosis and discontinuation of antibiotics in bacterial infections, as well as assessment of literature for these biomarkers in severity and bacterial co-infections in COVID-19.
DSCSA Update: Are You Ready for 2023?
The Drug Quality and Security Act (DQSA) outlines steps to achieve interoperable, electronic tracing of products at the package level to identify and trace certain prescription drugs as they are distributed in the United States. These requirements are mandated to take effect in 2023 and require members to implement various processes in order to be compliant with this act. Members will receive an overview of the DSCSA act, along with discussions on what it will take to operationalize and the impact these new requirements will have on the day to day operations of their pharmacies.
Target Audience
Pharmacists
Pharmacy Technicians
Learning Objectives
10/26/2022 – 340B Drug Discount Program Updates – 1.00 Contact Hours |
Gregory Medley, PharmD, MBA, 340B ACE, FASCPSenior Director, 340B Drug Pricing Program Services340B Apexus Certified ExpertVizient
|
Pharmacist Learning Objectives: |
|
|
|
Pharmacy technician Learning Objectives: |
|
|
|
10/27/2022 – Biomarker Utilization in the Evaluation of Infection – 1.00 Contact Hours |
Sarah Harrison, PharmD, BCCCSPExecutive Pharmacy DirectorVizient
|
Pharmacist Learning Objectives: |
|
|
|
Pharmacy technician Learning Objectives: |
|
|
|
10/27/2022 – DSCSA Update: Are you ready for 2023? – 1.00 Contact Hours |
Carolyn Liptak, MBA, RPhPharmacy Executive DirectorCenter for Pharmacy Practice ExcellenceVizient |
Pharmacist Learning Objectives: |
|
|
Pharmacy technician Learning Objectives: |
|
Additional Information
Attachment | Size |
---|---|
Helpful Tips for Users - Vizient CE System.pdf | 134.81 KB |
2022 Annual NPN Pharmacy Virtual Meeting - Multiday Information for CE.docx | 127.1 KB |
Faculty
Gregory Medley, PharmD, MBA, 340B ACE, FASCP
Senior Director, 340B Drug Pricing Program Services
340B Apexus Certified Expert
Vizient
Sarah Harrison, PharmD, BCCCSP
Executive Pharmacy Director
Vizient
Carolyn Liptak, MBA, RPh
Pharmacy Executive Director
Center for Pharmacy Practice Excellence
Vizient
Planning committee
Branka Milicev, PharmD,MBA
Pharmacy Executive Director
Vizient
Kim Bentley, CHCP
CE Program Manager
Vizient
Identification, Mitigation, and Disclosure of Relevant Financial Relationships
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
Disclosure of Financial Relationships:
Absence of Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.
Statement of Content Validity
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
FDA off-label/unapproved usage
Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.
Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.
In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Designation Statement(s):
PHARMACY
Vizient, Inc. designates this activity for a maximum of 3.00 ACPE credit hours.
JA0006103-0000-22-153-L04-P
JA0006103-0000-22-153-L04-T
OTHER
Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation indicating the maximum credits available. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re-certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.
Available Credit
- 3.00 ACPE Pharmacist
- 3.00 ACPE Pharmacy Technician
- 3.00 General CE - Attendance